- Home
- KPRX vs FTHM Comparison
KPRX vs FTHM Comparison
Compare KPRX & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KPRX | FTHM |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 11.4M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KPRX | FTHM |
|---|---|---|
| Price | $1.42 | $0.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 53.4K | ★ 214.7K |
| Earning Date | 11-17-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.71 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $420,477,000.00 |
| Revenue This Year | N/A | $9.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 25.45 |
| 52 Week Low | $1.55 | $0.17 |
| 52 Week High | $2.91 | $1.52 |
Technical Indicators
Market Signals| Indicator | KPRX | FTHM |
|---|---|---|
| Relative Strength Index (RSI) | 21.89 | 21.98 |
| Support Level | N/A | N/A |
| Resistance Level | $2.63 | $0.92 |
| Average True Range (ATR) | 0.17 | 0.02 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 2.56 | 2.36 |
Price Performance
Historical ComparisonAbout KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.